Related Experiment Video
Updated: Jul 11, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers
Jacqueline F Doody1, Ying Wang, Sheetal N Patel
1ImClone Systems Incorporated, 180 Varick Street, New York, NY 10014, USA.
Abstract:
Mutations in the kinase domain of the epidermal growth factor receptor (EGFR) were identified in approximately 15% of all patients with non-small cell lung cancer (NSCLC). These mutations have been established as an indicator of superior response to gefitinib and erlotinib, small molecule inhibitors of the EGFR kinase domain. Whether these mutations would also render patients more susceptible to treatment with cetuximab (Erbitux), an EGFR-neutralizing antibody, is yet to be determined. In this study, we attempted to evaluate the effect of cetuximab on several NSCLC lines harboring some of the more common EGFR mutations (L858R and delL747-T753insS), as well as the recently identified kinase inhibitor-resistant mutation, T790M. We could show that the kinase activity of the abovementioned EGFR mutants was hindered by cetuximab, as detected by both cell-based phosphorylation and proliferation assays. Interestingly, cetuximab also induced enhanced degradation of the EGFR mutants as compared with the wild-type receptor. Most importantly, cetuximab successfully inhibited the growth of NSCLC lines in xenograft models. These results indicate the promising potential of cetuximab as a regimen for patients with NSCLC bearing these mutations.
Insights
Cetuximab effectively targets epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC). This EGFR-neutralizing antibody inhibits mutant EGFR kinase activity and reduces tumor growth in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Activating mutations in the epidermal growth factor receptor (EGFR) kinase domain occur in ~15% of non-small cell lung cancer (NSCLC) patients.
- These EGFR mutations predict response to EGFR tyrosine kinase inhibitors like gefitinib and erlotinib.
- The efficacy of EGFR-neutralizing antibodies, such as cetuximab, against mutant EGFR in NSCLC remains largely undetermined.
Purpose of the Study:
- To evaluate the anti-cancer effects of cetuximab on NSCLC cell lines harboring common and resistant EGFR mutations.
- To assess cetuximab's impact on mutant EGFR kinase activity, proliferation, and degradation.
- To determine cetuximab's efficacy in inhibiting NSCLC tumor growth in vivo.
Main Methods:
- Utilized NSCLC cell lines with specific EGFR mutations (L858R, delL747-T753insS, T790M).
- Performed cell-based assays to measure EGFR phosphorylation and cell proliferation.
- Conducted xenograft studies in mice to assess tumor growth inhibition.
Main Results:
- Cetuximab effectively inhibited the kinase activity of common and resistant EGFR mutants.
- Cetuximab treatment led to reduced proliferation in NSCLC cell lines with EGFR mutations.
- Enhanced degradation of mutant EGFR was observed following cetuximab treatment compared to wild-type EGFR.
- Cetuximab demonstrated significant inhibition of NSCLC tumor growth in xenograft models.
Conclusions:
- Cetuximab hinders the kinase activity of various EGFR mutants in NSCLC.
- Cetuximab promotes the degradation of mutant EGFR.
- Cetuximab shows promising therapeutic potential for NSCLC patients with specific EGFR mutations.
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...